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BaCKgRoUND aND aIMS: Lifetime risk of biliary tract 
cancer (BTC) in primary sclerosing cholangitis (PSC) may 
exceed 20%, and BTC is currently the leading cause of death in 
patients with PSC. To open new avenues for management, we 
aimed to delineate clinically relevant genomic and pathological 
features of a large panel of PSC-associated BTC (PSC-BTC).
appRoaCH aND ReSUltS: We analyzed formalin-fixed, 
paraffin-embedded tumor tissue from 186 patients with PSC-
BTC from 11 centers in eight countries with all anatomical 
locations included. We performed tumor DNA sequencing at 
42 clinically relevant genetic loci to detect mutations, translo-
cations, and copy number variations, along with histomorpho-
logical and immunohistochemical characterization. Regardless 
of the anatomical localization, PSC-BTC exhibited a uniform 
molecular and histological characteristic similar to extrahe-
patic cholangiocarcinoma. We detected a high frequency of 
genomic alterations typical of extrahepatic cholangiocarcinoma, 
such as TP53 (35.5%), KRAS (28.0%), CDKN2A (14.5%), and 
SMAD4 (11.3%), as well as potentially druggable mutations 
(e.g., HER2/ERBB2). We found a high frequency of nontypi-
cal/nonductal histomorphological subtypes (55.2%) and of the 
usually rare BTC precursor lesion, intraductal papillary neo-
plasia (18.3%).
CoNClUSIoNS: Genomic alterations in PSC-BTC include 
a significant number of putative actionable therapeutic targets. 
Notably, PSC-BTC shows a distinct extrahepatic morpho- 
molecular phenotype, independent of the anatomical location of 
the tumor. These findings advance our understanding of PSC-
associated cholangiocarcinogenesis and provide strong incentives 
for clinical trials to test genome-based personalized treatment 
strategies in PSC-BTC. (Hepatology 2020;72:1253-1266).
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, often associated with inflammatory bowel disease.(1) In the absence of 
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any effective medical treatment, progressive bile duct 
injury and cholestasis lead to end-stage liver disease in 
most patients. In addition, patients with PSC experi-
ence a greatly increased risk of neoplasia arising from 
the biliary epithelium, including cholangiocarcinoma 
(CCA) and gallbladder carcinoma (GBC). Malignancy 
reduces overall patient survival significantly and cur-
rently serves as the most frequent cause of PSC-related 
death.(2) The reported cumulative risk of BTC devel-
opment in PSC ranges from 6%-22% for CCA and 
1%-4% for GBC.(1,3,4) Patients with PSC are young, 
and the high risk of an often incurable cancer poses an 
important unmet clinical need. The pathophysiologi-
cal basis of the high risk of BTC in PSC is not clear, 
but chronic inflammation in the context of the biliary 
microenvironment is likely to play a key role.
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In the United States and Europe, CCA is gener-
ally considered relatively rare (less than 6 per 100,000 
population), with PSC as a predominant risk factor.(5) 
CCA is more frequent in Southeast Asia (up to 113 per 
100,000 person-years), primarily due to endemic fluke 
infections with Opisthorchis viverrini or Clonorchis sin-
ensis.(6) The main subtypes of CCA are represented by 
extrahepatic CCA, including perihilar CCA (pCCA or 
Klatskin tumors) and distal extrahepatic CCA (dCCA), 
and intrahepatic CCA (iCCA). The spectrum of sub-
types of CCA in PSC have not been precisely defined, 
but tumors are frequently located in the perihilar and 
distal extrahepatic regions. Histologically, CCA and 
GBC from other etiologies consist of ductal/glandular/
tubular/acinar (i.e., not otherwise specified [NOS]) ade-
nocarcinomas in about 90% of cases, whereas the histo-
logic patterns of PSC-BTC have not yet been evaluated 
in comprehensive cohorts. Although there are data that 
suggest there are effective measures for surveillance of 
cholangiocarcinoma in PSC, it is notoriously difficult 
to differentiate benign from malignant biliary strictures, 
leading to late diagnosis in most cases.(7) Surgery either 
by resection or liver transplantation represents the only 
curative intent treatment for PSC-CCA. Only one-
third of the patients are candidates for radical surgery at 
the time of CCA diagnosis, and the local recurrence rate 
after surgery is above 60%.(8) Liver transplantation fol-
lowing neoadjuvant radiotherapy with chemosensitiza-
tion may provide improved survival for highly selected 
patients with early-stage, unresectable perihilar CCA.(9) 
The benefit of current palliative systemic chemotherapy 
regimens is limited, with median overall survival less 
than 12 months using first-line treatment with gemcit-
abine and cisplatin.(10)
As an established branch of personalized medicine, 
profiling of somatic mutations in tumor DNA has 
identified clinically relevant genomic alterations in key 
pathways of prognostic and therapeutic relevance.(11) 
In BTC derived from other etiologies than PSC, sev-
eral molecular genetic alterations have been identified 
across multiple tumor-suppressor genes and oncogenes, 
such as KRAS (Kirsten rat sarcoma viral oncogene 
homolog), TP53 (tumor protein 53), SMAD4 (mothers 
against decapentaplegic homolog 4), CDKN2A (cyclin- 
dependent kinase inhibitor 2A), ERBB1/2 (erythro-
blastic leukemia viral oncogene homolog 1/2), FGFR  
(fibroblast growth factor receptor), and IDH1/2 (isoc-
itrate dehydrogenase 1/2).(11-14) Previous efforts have 
revealed that genomic alterations in BTC differ 
according to the anatomical subtypes of BTC and caus-
ative etiology, guiding the transformation of findings 
from different anatomical and etiological subtypes into 
diagnostic and treatment algorithms.(11,15) As such, 
molecular profiling of different BTC subtypes high-
lights different clusters of genomic alterations that con-
verge into functional categories that may enable future 
precision oncology approaches.(14)
The fraction of PSC patients in exome-sequencing 
studies of BTC has been low (less than 2% known 
cases with underlying PSC).(11,14) Given the pros-
pects for diagnostic and therapeutic improvements 
for patients with PSC, we herein aimed to integrate 
findings from these studies with generic cancer-gene 
panels to perform a focused assessment of clinically 
relevant mutations in PSC-associated BTC using 
targeted resequencing. We hypothesized that an 
enhanced understanding of the molecular carcinogen-
esis would delineate molecular driver lesions of rele-
vance and potentially identify druggable targets.
Materials and Methods
patIeNt SaMpleS aND 
ClINICopatHologICal Data
We used archived, formalin-fixed, paraffin-embedded 
(FFPE) specimens obtained from explanted livers, partial 
liver resections, cholecystectomies, or biopsies performed 
between 1996 and 2016 for the purpose of diagnosis or 
treatment of PSC-BTC. In total, we collected 224 PSC-
BTC samples from 11 centers in Europe and the United 
States. After initial analysis, 38 samples were excluded 
based on the histomorphological criteria (mostly insuf-
ficient tumor material), tumor cellularity less than 10%, 
or low DNA content or quality (total dropout rate of 
17%). The final panel submitted to further mutational 
profiling, consisting of 186 PSC-BTC tissue specimens. 
Clinical follow-up data were available for 160 patients.
Diagnosis of PSC was based on standard clinical, 
biochemical, cholangiographic, and histological crite-
ria.(8) Detailed clinical data and histopathological infor-
mation were available for 174 patients (Tables 1 and 2 
and Supporting Table S1). Two board-certified pathol-
ogists (B.G. and P.S.) validated the histopathological 
diagnosis of CCA and GBC. Staging of the tumors was 
performed according to the American Joint Committee 
on Cancer (AJCC) classification, 8th edition.
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etHICal appRoVal
Written informed consent was obtained from all 
study subjects at each center if possible. For long-
time archived samples, where this was not possible, 
an exemption from informed consent was obtained 
by the local ethical committee to allow the use of 
the samples. Study protocols were approved by the 
ethics committees of all recruiting centers as well as 
the Regional Committees for Medical and Health 
Research Ethics of South East Norway (6.2008.1723) 
and the ethical board of the University Hospital 
Heidelberg, Germany (206/05).
paNel SeQUeNCINg
For DNA and RNA extraction and process-
ing, see Supporting Information. Massive parallel 
sequencing was performed using three panels: (1) 
a custom PSC-BTC panel that consisted of 284 
primer pairs (amplicons) covering 165 exons of 
40 genes frequently mutated in hepato-pancreato- 
biliary cancers (2), a custom panel covering 27 hepa-
tobiliary cancer–associated gene translocations, and 
(3) the commercial Oncomine BRCA (breast cancer 
antigen) panel covering all exons of BRCA1 (113 
amplicons) and BRCA2 (152 amplicons) (Thermo 
Fisher Scientific, Waltham, MA) (see Supporting 
Table S2). All variants were inspected manually 
using the IGV browser, and the limit of detection 
was set at 5% to avoid false-positive results due to 
C > T transitions (deamination artifacts introduced 
by formalin fixation).
IMMUNoHIStoCHeMIStRy, 
CHRoMogeN IN SITU 
HyBRIDIZatIoN, aND 
MoleCUlaR MICRoSatellIte 
INStaBIlIty aNalySIS
Tissue microarrays (TMAs) were fabricated for 
all 95 cases of which sufficient tissue block material 
was available (Supporting Table S3). For immuno-
histochemical (IHC) staining and chromogen in situ 
hybridization (CISH), 3-µm sections of the TMA 
were used.
Technical details of the IHC and CISH analy-
ses are provided in the Supporting Information and 
in Supporting Tables S3 and S5. For details on the 
molecular microsatellite instability (MSI) analysis, see 
the Supporting Information.
StatIStICal aNalySIS
The extensive tissue panel with samples from 
tumors originating from all anatomical subsites 
allowed for subgroup assessments, including analyses 
of frequencies of mutations and interrelationship of 
mutations among the anatomical subtypes. Graphical 
representations of mutational frequencies in the total 
BTC panel and in the anatomical BTC subtypes by 
oncoplot, circos plots, and PCA were created by the 
publicly available R-packages ComplexHeatmap, cir-
clize, and factoextra (Figs. 1 and 2 and Supporting 
Fig. S4). Due to limitations in visualizing multidi-
mensional data, only pair-wise co-occurrences are 
represented in the circos plots. Frequencies shown by 
the oncoplots are on a sample per-gene basis and do 
not take into account that some genes may contain 
more than one mutation in the same tumor sample.
The publicly available data of Wardell et al., J 
Hepatology 2018 were analyzed for the 12 genes 
with highest frequencies of alterations in our panel 
(TP53, KRAS, CDKN2A, SMAD4, PIK3CA [phos-
phoinositide-3-kinase, catalytic, alpha polypeptide], 
CDKN2B, ERBB2, ROBO1 [roundabout homolog 1], 
KDM6A [lysine demethylase 6A], FBXW7 [F-box 
and WD repeat domain containing 7], GNAS [gua-
nine nucleotide binding protein (G protein), alpha 
taBle 1. Study Samples and tumor Subtype of the pSC-BtC 
panel (n = 186)
Number (Percent) Invasive (n = 174) HGD (n = 12)
Tumor subtype
iCCA 60 (32.3) —
pCCA 64 (34.4) 6 (3.2)
dCCA 18 (9.7) —
xCCA 4 (2.2) 1 (0.5)
GBC 28 (15.1) 5 (2.7)
Sampling procedure*
Biopsy 36 (19.4) 1 (0.5)
Resection 96 (51.6) 8 (4.3)
Liver explant 42 (22.6) 3 (1.6)
Note: HGD = high-grade noninvasive biliary neoplasia (i.e., IPNB 
or BilIN-3).
*Sampling procedure of the analyzed samples according to an as-
sessment of the histological material and available clinicopatho-
logical data.
Abbreviations: xCCA, cholangiocarcinoma of unknown anatomi-
cal subtype.
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stimulating activity polypeptide 1], and TGFBR2) in 
the BTC subgroups iCCA, pCCA, dCCA, and GBC 
(Supporting Table S8).(15)
We examined associations between genomic alter-
ations and overall survival using the endpoint of 
BTC-related death. Only one patient died due to a 
PSC-unrelated cause and was therefore censored. The 
baseline time point used in the survival analysis was 
BTC diagnosis. Statistical analysis and visualization 
was performed using the computing environment R 
(http://www.R-proje ct.org/) and GraphPad Prism 6. 
Median survival and the corresponding 95% confi-
dence intervals were calculated by Kaplan-Meier sur-
vival analysis, and the survival distributions for each 
category were compared using the log-rank test. All 
reported P values were two-sided, and P  <  0.05 was 
taBle 2. Clinical and Histopathological Data of the  
pSC-BtC panel (n = 174)
Number (Percent)
Patients with PSC* 174 (100.0)
Mean age at BTC diagnosis 48.1 years
Overall survival†
2-year survival (%) 47.0
5-year survival (%) 21.6
Sex
Male 128 (73.6)
Female 46 (26.4)
Operation procedure‡
Biospy 34 (19.5)
Resection 84 (48.3)
Liver transplantation 56 (32.2)
Subtype
iCCA 60 (34.5)
pCCA 64 (36.8)
dCCA 18 (10.3)
xCCA 4 (2.3)
GBC 28 (16.1)
Histology
NOS|| 74 (42.5)
Papillary 23 (13.2)
Mucinous 41 (23.6)
Solid 19 (10.9)
Diffuse 7 (4.0)
Intestinal 3 (1.7)
Adenosquamous 3 (1.7)
NA 4 (2.3)
AJCC§
AJCC 0 3 (1.7)
AJCC 1 9 (5.1)
AJCC 2 22 (12.5)
AJCC 3 45 (25.6)
AJCC 4 38 (21.6)
NA 57 (32.4)
pT
T1 18 (10.2)
T2 54 (30.7)
T3 32 (18.2)
T4 17 (9.7)
NA 53 (30.1)
pN
N0 46 (26.1)
N1 67 (38.1)
NA 61 (34.7)
M
M0 93 (52.8)
M1 38 (21.6)
NA 43 (24.4)
 
Number (Percent)
G
G1 3 (1.7)
G2 131 (74.4)
G3 36 (20.5)
NA 4 (2.3)
R
R0 18 (10.2)
R1 11 (6.3)
R2 5 (2.8)
NA 140 (79.5)
L/V
L/V0 14 (8.0)
L/V1 22 (12.5)
NA 138 (78.4)
Pn
Pn0 11 (6.3)
Pn1 12 (6.8)
NA 151 (85.8)
*Detailed clinical data and histopathological information were 
available for 174 patients.
†Overall survival was available for n = 160 patients.
‡Twelve patients with resection and 2 patients with biopsy at the 
time of diagnosis received liver transplantation afterward.
§Cases with NA for pN had no lymph nodes resected; therefore, 
AJCC status could not be assessed.
||NOS = typical ductal/glandular/tubular/acinar histologic pheno-
type of BTC.
Abbreviations: G, grade of differentiation; L/V, invasion into lym-
phatic vessels/veins; M, distant metastases; NA, not available; pN, 
histopathologic lymph node evaluation; Pn, perineural invasion; pT, 
histopathologic tumor stage evaluation; R, resection margins.
taBle 2. Continued
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considered statistically significant. Enrichment anal-
ysis was done using Fisher’s exact test. If more than 
two groups were compared, pairwise comparisons 
were done for all combinations using Fisher’s exact 
test, and false-discovery rate correction of the P values 
was performed according to Benjamini-Hochberg.
Graphical representations of mutational differ-
ences by oncoplot and circos plots were created by the 
FIg. 1. Mutational landscape of PSC-BTCs. (A) Schematic overview of the study design. (B) Oncoplots of genes sorted by frequency of 
mutations in all BTC samples. Missense mutations, inframe mutations, truncations, and CNAs with frequencies greater than 2% across 
the panel of PSC-BTC patients (n = 186). (C) Circos plot representing co-occurrence of mutations. A band connecting genes represents 
co-occurring mutations in a given patient. The width of the band represents the frequency of this mutation pair within the data set. 
Abbreviations: CNA, copy number alteration; TRUNC, truncation; QC, quality control.
A
B
C
11 international
PSC centers
(224 patients)
QC
PSC-BTC
samples
(186 patients)
Invasive BTC
(174 patients)
Panel Sequencing
High-grade
Dysplasia
(12 patients)
Clinicopathological data
Invasive only
(150 patients)
Invasive &
IPNB
(24 patients)
Dysplasia &
Invasive BTC
(7 patients)
Dysplasia only
(5 patients)
IPNB
(6 patients)
BiIIN grade 3
(1 patient)
IPNB
(4 patients)
BiIIN grade 3
(1 patient)
Alterations
TRUNC
CNA
INFRAME
MISSENSE
TP53
KRAS
CDKN2A
SMAD4
PIK3CA
CDKN2B
ERBB2/3
KDM5A/6A
ROBO1
FBXW7
TGFBR2
GNAS
SMARCA4
BRAF
ARID1A
EGFR
FGFR2
FGF23
35.5%
28.0%
14.5%
11.3%
9.1%
8.6%
8.1%
7.0%
7.0%
4.3%
4.3%
4.3%
3.8%
3.8%
3.2%
2.7%
2.7%
2.2%
10
8
6
4
2
0
0 10 20 30 40
TP53
S
A
R
K
CD
KN
2A
SMAD4
CDKN2B
ERBB2/3
P
IK
3C
A
K
D
M
5/6A R
O
B
O
1
FB
X
W
7
G
N
A
S
TG
FB
R2
BR
AF
SM
AR
CA
4
AR
ID1
A
EGF
R
FGFR2
FGF23
FGF10
Hepatology, Vol. 72, No. 4, 2020 GOEPPERT, FOLSERAAS, ET AL.
1259
FIg. 2. Mutational landscape of different subtypes of PSC-associated BTC. (A) Oncoplots of genes sorted by frequency of mutations 
in all BTC subtypes. Missense mutations, inframe mutations, TRUNCs, and CNAs of 146 patients with recurrent mutations are shown. 
Circos plots depicting interrelationships of mutations stratified by PSC-BTC-subtypes: iCCA (B), pCCA (C), dCCA (D), and GBC (E).
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publicly available R-package circlize (see Supporting 
Information).(16)
Putative actionable targets were identified using the 
TARGET (tumor  alterations relevant for  genomics- 
driven therapy) database version 3 by Broad Institute 
(http://archi ve.broad insti tute.org/cance r/cga./
target).(17)
Results
ClINICal CHaRaCteRIStICS
Tumor samples from 186 patients with PSC-BTC, 
including 174 (93.5%) invasive carcinomas and 12 
(6.5%) high-grade noninvasive biliary neoplasms, were 
analyzed by panel sequencing (Table 1 and Fig. 1). 
The panel of patients with PSC-BTC showed a male 
preponderance (128 of 174; 73.6%; Table 2). The 
mean age at diagnosis of PSC was 41.6 years (range: 
11.9-73.5  years), and at diagnosis of BTC was 
48.1 years. Overall survival of patients with PSC- was 
poor, with a 5-years survival rate of 21.6% (n = 160; 
Table 2).
HIStoMoRpHology aND paNel 
SeQUeNCINg ReVealeD aN 
eXtRaHepatIC pHeNotype oF 
pSC-BtC
According to the anatomical location, the patient 
panel consisted of 60 iCCAs, 64 pCCAs, 18 dCCAs, 
28 GBCs, and 4 samples of unknown anatomical origin 
(Table 1). CCA was sampled from explant liver tissue 
obtained at liver transplantation in 37 of 186 patients 
(9 iCCAs, 24 pCCAs, 2 dCCAs, and 2 with unknown 
anatomical origin). Among the 37 patients with find-
ings of CCA in explant liver, 30 of 37 (81.1%) were 
incidental findings, whereas 7 of 37 (18.9%) among the 
CCAs were diagnosed before the transplant.
Analysis of available clinicopathological data and 
histomorphological evaluation revealed a relatively 
high frequency of non-NOS histologic subtypes. In 
detail, only 74 of 174 (44.8%) of the invasive PSC-
BTCs showed a typical NOS (ductal/glandular/ 
tubular/acinar) histomorphology, whereas 96 of 174 
(55.2%) showed a non-NOS histomorphology (i.e., 
papillary, mucinous, solid, diffuse, intestinal, or ade-
nosquamous) (Table 2). A cholangiolar/small-duct 
histology was observed in only one (1 of 60, 1.7%) 
iCCA. Moreover, 34 patients with PSC-BTCs (18.3%) 
showed intraductal or intracystic papillary neoplasms of 
the bile duct (PSC-IPNB). Of these 34 patients with 
PSC-IPNB, 30 were associated with invasive CCA, 
whereas 4 patients had IPNB without invasive CCA 
(Fig. 1A). Two patients with high-grade precursor 
biliary intraepithelial neoplasm with grade 3 (BilIN-
3) lesions were included: one BilIN-3 was associated 
with invasive BTC and one was not (Fig. 1A and 
Supporting Fig. S1). Tumor grading was performed for 
the invasive carcinomas and showed a predominance 
of moderate grade (131 of 174; 74.4%) (Table 2).
In 146 (78.5%) of the 186 BTC samples analyzed 
by massive parallel sequencing, a total of 247 nonsyn-
onymous mutations and 89 copy number alterations 
(CNAs) in 30 of 42 targeted genes were identified 
(Fig. 1B and Supporting Table S6). Principal com-
ponent analysis (PCA) of the mutational profiles 
revealed that patient samples did not cluster by clini-
cal center or by AJCC staging (Supporting Fig. S2B). 
Among the 247 nonsynonymous mutations identi-
fied, 184 mutations were missense mutations, 56 were 
truncations, and 7 were in-frame insertions or dele-
tions (Supporting Tables S6 and S7). Genomic alter-
ations within TP53 (35.5%, including 34.4% missense 
mutations and truncations), KRAS (28.0%, including 
24.7% missense mutations), CDKN2A (14.5%, includ-
ing 7% deletions), SMAD4 (11.4%), PIK3CA (9.1%), 
CDKN2B (8.6%), ERBB2 (8.1%), KDM5A/6A (7.0%), 
and ROBO1 (7.0%) were most common, with a second 
tier of less frequently mutated genes (2%-5%) includ-
ing FBXW7, TGFBR2, GNAS, SMARCA4 (SWI/SNF 
Related, Matrix Associated, Actin Dependent Regulator 
Of Chromatin, Subfamily A, Member 4), BRAF, and 
ARID1A (AT-Rich Interaction Domain 1A) (Fig. 1B). 
Interrelationships among the genes harboring non-
synonymous mutations showed that co-occurrences of 
TP53 with KRAS alterations and KRAS with CDKN2A 
were most common (Fig. 1C). Transitions of both C to 
T and G to A mutations (C > T | G > A) represented 
the predominant mutation in all subtypes. The number 
of mutations per tumor ranged from one to six with a 
mean of 1.84 ± 1.12 (mean ± SD) mutations per tumor. 
The mean number of nonsynonymous mutations per 
tumor was 2.06 ± 1.39 for GBC, 1.86 ± 1.10 for CCA, 
and 1.36 ± 0.50 for the noninvasive high-grade dysplastic 
precursor lesions (HGDs). Thus, CCA and GBC shared 
a comparable number of mutations per sample, whereas 
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the mean number of mutations in HGDs was signifi-
cantly lower compared with the invasive BTC samples 
(P  =  0.01). CNAs were found primarily in CDKN2B 
(7.5%), CDKN2A (7.0%), and ERBB2 (4.3%).
In 40 tumors (21.5%), no mutation was detected by 
panel sequencing of the 42 targeted genes. In the entire 
patient panel, including n = 60 iCCAs, no FGFR trans-
location or deleterious BRCA1/2 mutation and only 
one IDH1 (p.R132C) mutation (in a single CCA with 
typical small-duct/cholangiolar histomorphology) were 
detected (Fig. 2A and Supporting Table S6).(18)
pUtatIVe aCtIoNaBle taRgetS 
IN pSC-BtC
Of the 30 genomically altered genes, 19 are consid-
ered actionable according to the TARGET database 
version 3 by the Broad Institute.(17) A total of 116 
(62.4%) samples had mutations within one or more 
potentially actionable genes, and 49 samples (26.3%) 
had two or more potentially actionable genes (see 
Supporting Table S9 for full results).
For a subset of the PSC-BTC panel (n = 95), we 
were able to construct a TMA and perform additional 
analyses using IHC and CISH (Supporting Fig. S3). 
Using the guidelines for HER2 testing in gastric can-
cer, 8 of 95 (8.4%) cases showed HER2 amplification 
(see Supporting Table S3). Additionally, immunore-
activity was observed in 39 of 82 (47.6%) patients for 
epidermal growth factor receptor (EGFR), in 29 of 
87 (33.3%) for c-Met, in 1 of 88 (1.1%) for c-Myc, 
and in 20 of 84 (23.8%) of the analyzed PSC-BTCs 
for programmed death ligand 1 (PD-L1). MSI anal-
ysis using mononucleotide MSI markers (BAT25, 
BAT26, and CAT25) and IHC for the DNA mis-
match repair proteins (MSH2, MSH6, MLH1, and 
PMS2) revealed no MSI-high case in all analyzed 
PSC-BTCs (0 of 95). Detailed results of IHC analy-
ses are found in Supporting Table S3.
CoRRelatIoN oF MoleCUlaR 
alteRatIoNS WItH 
ClINICopatHologICal Data 
aND FolloW-Up
Comparison of the three anatomical subgroups of 
PSC-associated BTC, including CCA (iCCA, pCCA, 
and dCCA) and GBC, showed a homogenous muta-
tion profile with no statistically significant differences 
in frequencies of detected genomic alterations (Fisher’s 
exact test; Fig. 2A and Supporting Figure S4). The 
interrelationship analysis by circos plots performed in 
all BTC subtypes separately showed a similar picture 
(Fig. 2B-E).
Clinical follow-up data were available for 160 of 
the 186 PSC-BTC patients. During follow-up, as 
many as 60% of the patients received liver transplan-
tation, which was associated with significantly pro-
longed patient survival (Supporting Fig. S5 and Table 
S4). Patient overall survival showed stratification by 
tumor AJCC stages (P < 0.001; Fig. 3A). Correlation 
analyses between the mutational profiles did not show 
statistically significant associations with histological 
phenotype and AJCC staging (Fisher’s exact test). 
In addition, comparison of the number of nonsyn-
onymous mutations in PSC-BTC subtype-specific 
analyses was not statistically significant (Fisher’s exact 
test). No statistically significant association between 
the number of detected molecular alterations in 
PSC-BTCs and patient overall survival was found 
(Supporting Fig. S6). Observed center-specific differ-
ences in patient overall survival were correlated with 
differences of tumor AJCC stages between the con-
tributing centers. Patient subtypes and clinicopatho-
logical data are described in detail in Table 2 for the 
entire patient panel and in Supporting Table S1 strat-
ified by contributing centers.
The histomorphological phenotype was associated 
with overall survival in patients with PSC-BTC. A 
solid growth pattern showed a significantly shortened 
overall survival compared with all other histological 
phenotypes, whereas papillary histology showed a bet-
ter overall survival compared with other histomorpho-
logical subtypes (Fig. 3B).
The analysis of single mutations with overall 
patient survival revealed significant negative effects 
on overall survival in patients with tumors harboring 
mutations in KRAS (n = 46, P = 0.027; Fig. 4A-D and 
Supporting Fig. S7). Patients with nonsynonymous 
mutations in more than one of the analyzed genes did 
not show statistically significant differences in overall 
survival (Supporting Fig. S6).
Discussion
We present herein an integrated morphological and 
genomic analysis of a large and clinicopathologically 
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well-characterized PSC-BTC patient panel. Despite 
limitations posed by the FFPE basis, which restricted 
the assessment to targeted resequencing while allow-
ing statistical power through sample size, our data 
define a common histomorphologic phenotype and 
the predominant molecular alterations in PSC-driven 
biliary carcinogenesis. Importantly, we identified a 
number of potential targets for individualized therapy 
in a patient group that is currently largely devoid of 
nonsurgical management options.
Previous studies have documented that genomic 
alterations in BTC differ according to etiology and 
anatomical location.(11-15) With regard to etiology, 
our BTC panel is exceptionally homogenous, as 
all BTC samples in the cohort were derived from a 
monoetiological background of PSC. The analysis of 
a large number of samples from a single BTC eti-
ology allowed us to correlate the molecular findings 
with various clinicopathological data and anatomical 
location for common motifs of PSC-BTC. Genomic 
differences among the anatomical subtypes have been 
driven primarily by mutations in certain genes, but 
also partly by variability in gene sets mutated across 
subtypes.(11,15) A key finding of our study is that 
PSC-BTC exhibits a phenotype that is characteris-
tic of extrahepatic, large-duct BTC, independent of 
the anatomical location of the tumor.(11-14) When 
comparing the mutational frequencies of the most 
commonly mutated genes in our PSC-BTC panel 
with the data published on polyetiological, mostly 
non-PSC-associated BTCs, we observed that our 
PSC-BTC panel showed mutational frequencies that 
are well comparable to extrahepatic CCAs (including 
pCCA and dCCA).(15) Importantly, this observation 
includes a large number of tumors with an intrahe-
patic location (34.5% of the panel), which were still 
histologically and molecularly indistinguishable from 
PSC-CCAs of extrahepatic origin. Furthermore, these 
intrahepatic tumors lacked the genomic alterations 
characteristic of iCCA (e.g., IDH1/2 mutations and 
FGFR2 translocations).(11,18)
Among the 60 intrahepatic tumors in our panel, 
signature mutations of iCCA were absent, except for a 
single case with an IDH1-mutation that also included 
the only case in the patient panel with a small duct/
cholangiolocellular histomorphology otherwise pres-
ent in up to 40% of iCCAs.(18,20) This mutation may 
have occurred sporadically in this patient. Noteworthy, 
FIg. 3. Overall survival data of patients with PSC-BTC. (A) Overall survival data of 160 of the 186 analyzed patients with PSC-
BTC stratified by AJCC staging. (B) Overall survival data of all analyzed patients with PSC-BTC stratified by histological phenotype. 
Abbreviations: AJCC, American Joint Committee on Cancer Classification; NA, not available.
A B
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FGFR2 translocations, otherwise frequently observed 
in iCCA, were completely absent from the entire 
PSC-BTC patient panel, including all intrahepatic 
tumors.(11,14) Likewise, the histomorphological phe-
notype of our PSC-BTC cohort showed two main 
differences from non-PSC-BTC: (1) The small-duct 
type iCCA, now recognized as a distinct subtype of 
iCCA, was virtually not present in our monoetio-
logical PSC-BTC cohort (1 of 60, 1.7%), and (2) all 
other PSC-iCCA showed the large-duct type (59 of 
60, 98.3%), which is equivalent to an extrahepatic 
histomorphological phenotype, as seen in pCCA. In 
the non-PSC-BTC cohort, rarely seen non-NOS (i.e., 
non-ductal/glandular/tubular/acinar) histologic pat-
terns were very frequent in our PSC-BTC cohort (i.e., 
96 of 174 [55.2%] showed a non-NOS histomorphol-
ogy [e.g., papillary, mucinous, solid, diffuse, intestinal, 
or adenosquamous]).
Taken together, PSC-BTC displays a predom-
inantly large-duct BTC genotype and phenotype 
that presumptively result from common carcino-
genic pathways. This is of relevance for molecular 
testing and for planning of clinical trials of targeted 
therapies.(18,20)
The mutational profile of PSC-BTC is sim-
ilar to that observed in liver fluke–related BTC. 
Corresponding to the genomic profile in our PSC-
BTC panel, fluke-positive CCAs are enriched in 
TP53, SMAD4, ERBB2, and GNAS alterations, while 
fluke negative CCAs frequently exhibit IDH1/2 and 
FIg. 4. Overall survival data of patients with PSC-BTC in correlation to specific molecular alterations: KRAS (A), TP53 (B), CDKN2A/B 
(C), and SMAD4 (D). Abbreviations: MT, mutated; WT, wild type.
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FGFR-related alterations.(12-14) One explanation may 
be that both PSC and liver fluke disease represent 
chronic inflammatory conditions, which together with 
disruption of host bile homeostasis, result in chronic 
damage of bile duct epithelia and oxidative stress, 
predisposing to comparable oncogenic mutations. 
Another explanation may be the common cellular 
origin, as both conditions primarily affect large intra-
hepatic and extrahepatic bile ducts.(20,21) Differences 
between our PSC-BTC panel and available data from 
both sporadic-related and fluke-related BTC exist 
regarding the higher frequency of HER2 (ERBB2) 
alterations, identified in our panel predominantly in 
dCCAs (22.2%; 4 of 18) and GBC (14.3%; 4 of 28), 
but present in all anatomical subgroups.(11-15)
Unlike the situation in many other cancers, no tar-
geted treatment options are yet approved for BTC. 
The scarcity of therapeutic options, together with the 
lack of sensitive screening options, leads to high mor-
tality and poses an important unmet clinical need in 
patients with PSC. Thus, to identify genomic alter-
ations amenable to drugs approved for other tumor 
types or currently tested in clinical trials is of major 
interest. We detected potentially actionable mutations 
in 116 (62.4%) of the included patients according to 
the TARGET database (Supporting Table S8).(17) 
Examples include alterations in genes affecting PI3K/
Akt/mammalian target of rapamycin (e.g., PIK3CA, 
FBXW7), RAS/RAF/MEK/ERK (KRAS, BRAF, 
NRAS), and tyrosine kinase receptor signaling (e.g., 
EGFR [ERBB1], HER2 [ERBB2], ERBB3, FGFR2). 
ERBB2 mutations were identified in 8.1% (15 of 186) 
of the PSC-BTCs in our panel, and 8.4% (8 of 95) 
of the IHC/CISH accessible cases showed HER2 
amplifications. Anti-HER-2 treatment is approved 
long-term for breast cancer, stomach cancer, and 
gastroesophageal junction cancer with HER-2 over-
expression/amplification.(22-24) Several anti-HER2 
clinical trials and case reports show that HER2 is 
a promising target in BTC, but anti-HER2 agents 
are still not approved for routine administration in 
BTC.(25) EGFR alterations were identified in 2.7% (5 
of 186) of our cases. The anti-EGFR antibody cetux-
imab is approved for treatment of metastatic colorec-
tal cancer with wild-type K and N-RAS genes.(26) 
Various EGFR antibodies (cetuximab, erlotinib, and 
panitumumab) have been analyzed in various combi-
nations with gemcitabine in advanced BTC in phase 2 
and 3 clinical studies, but the clinical benefit of EGFR 
inhibitors in BTC is still unclear, and biomarkers pre-
dicting potential response to EGFR inhibition are 
needed.(27) Other targets with future treatment poten-
tial include CDKN2A/2B, which can be targeted by 
CDK4/6 inhibitors such as palbociclib, which have 
been applied for the treatment of breast cancer and 
currently are tested in phase 3 trials in pancreatic can-
cer (NCT03065062).(28)
Although we failed to detect MSI-high tumors 
in our PSC-BTC panel, immunoreactivity for 
PD-L1 was observed in 23.8% (20 of 84) of our 
cases, suggesting a therapeutic potential of immune 
checkpoint inhibitors.(29) Immunoreactivity for 
c-Met was observed in 33.3% (29 of 87) cases, 
indicating a potential for Met-targeted agents in 
PSC-BTC. Based on our data, further preclinical 
research and clinical studies are now warranted to 
explore the role of the molecular targets observed 
in PSC-BTC.
Prior genomic analyses in PSC-BTC have been 
limited to sequencing of KRAS and CDKN2A genes 
performed in considerably smaller PSC-BTC panels 
(n = 10-33 patients).(30-33) We found KRAS mutations 
in 28% of PSC-BTC, a number that is in line with 
previous studies.(30,31) Supported by our results, previ-
ous studies have also implicated CDKN2A inactivation 
in PSC-BTC carcinogenesis.(33) Presence of TP53 
mutations in PSC-BTC have previously only been 
investigated indirectly by estimating the accumulation 
of the TP53-encoded p53 protein in tumor tissue by 
IHC.(30-32) Reported rates of p53 overexpression show 
large variability in previous studies (31%-79%), which 
may be attributed to the detection mode of altered 
p53 expression as well as patient selection bias.(30-32) 
The current TP53 mutation frequency of 35.5% in 
PSC-BTC is likely a robust estimate, given the size 
and broad representation of the current patient panel.
Histomorphological evaluation of the PSC-BTC 
panel showed a high prevalence of rare histologic 
phenotypes.(34) Most prominently, a papillary subtype 
was frequent in PSC-BTC of all anatomical subtypes. 
This is in line with the finding that IPNB lesions were 
also more frequent in comparison to previous reports 
on non-PSC-associated BTC.(35) These morpholog-
ical findings may reflect the different environmental 
and molecular setting of PSC versus non-PSC-associ-
ated biliary carcinogenesis. Future mechanistic studies 
should attempt to elaborate on IPNB as a precursor 
lesion of PSC-BTC.
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Obvious limitations of this study are the retro-
spective character of the tissue and data collection 
as well as the limited genomic coverage intrin-
sic to the panel-sequencing approach. To enable a 
statistically informative study in this rare group of 
BTC, in which prospectively collected fresh frozen 
tissue is extremely scarce, we focused our recruit-
ment on establishing an adequately sized archived 
FFPE PSC-BTC material from explant livers, sur-
gical resections, or biopsies. The panel sequencing 
approach allowed for the use of FFPE material from 
these sources with an acceptable rate of excluded 
samples (17%; 38 of 224 samples) due to insuffi-
cient tumor material or low DNA content or quality. 
Selection bias, and putatively also a center bias, may 
have been introduced by indirectly enriching for 
resected and transplanted cases (i.e., an overrepre-
sentation of lower-stage cases). Despite this limita-
tion, a distribution of patients across all four AJCC 
stages was still achieved. Retrospective data also led 
to some degree of missing data, and together with 
the high transplantation frequency, limits the valid-
ity of survival analyses for certain subtypes, including 
the assessment of putatively prognostic mutations. 
Despite limitations, the study represents a major 
advance in being the largest molecular characteriza-
tion of PSC-BTC to date, and the analysis of histo-
pathological, clinical, and follow-up data allowed for 
several significant conclusions to be drawn.
In conclusion, our study demonstrated a common 
morpho-molecular phenotype across all anatomi-
cal locations of PSC-BTC. We also detected sev-
eral genetic abnormities relevant for future research 
into potential targeted therapies in this underserved 
patient group. Further characterization of PSC-BTC 
tissue panels and single cells using whole-exome and 
whole-genome sequencing in future studies is likely to 
expand on current observations.
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